medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 6

Siguiente >>

Ann Hepatol 2013; 12 (6)


Treatment of chronic hepatitis C virus infection in the near future

Cheinquer H

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 854-859
Archivo PDF: 90.98 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatology 2011; 55: 245-64.

  2. Ghany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.

  3. Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20: 524-9.

  4. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.

  5. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  6. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  10. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  11. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  12. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.

  13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  15. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S88-S100.

  16. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/ Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York. Gastroenterol Hepatol (NY) 2013; 9(Suppl. 3): 1-18.

  17. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1525.

  18. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment- naive patients: results from QUEST-2, a phase III trial. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1413.

  19. Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ ribavirin treatment: final SVR24 results of the ASPIRE trial. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22, 2012; Barcelona, Spain. Abstract 2.

  20. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.

  21. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.

  22. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.

  23. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of Viral Load through 4 Weeks Post-Treatment Results of a Once-daily Regimen of Simeprevir + Sofosbuvir with or without Ribavirin in Hepatitis C Virus GT 1 Null Responders. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 155LB.

  24. Ferenci P, Asselah T, Foster GR, et al. Falaprevir plus pegylated interferon alfa2a and ribavirin in chronic HCV genotype- 1 treatment-naïve patients: Final results from STARTVERSO1, a randomized, placebo-controlled phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 1416.

  25. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.

  26. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon- free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-1.

  27. Gane E, Stedman CA, Hyland RH, et al. All-oral sofosbuvirbased 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam. April 24-28, 2013. Abstract 14.

  28. Hezode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCVGenotype 1 or 4 Patients: Phase 2b COMMAND-1 SVR12 Results. Hepatology 2012; 56(Suppl. 1): 553A. Abstract 755.

  29. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir combined with peginterferon alfa 2a alfa-and ribavirin for 12 or 16 weeks in patients with hepatitis c virus genotype 2 or 3 infection: command gt 2/3 study. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1418.

  30. Everson GT, Sims KD, Rodriguez-Torres M, et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS- 791325 in treatment-naive, hepatitis C virus genotype 1- infected patients. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1417.

  31. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCG GT 1, 2, or 3. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9–13, 2012; Boston, Massachusetts. Abstract LB-2.

  32. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir plus/minus ribavirin (RBV) in chronic HCV genotype (GT) 1- infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1417.

  33. Shakespeare W. Henry V (act 3, scene 1).




2020     |     www.medigraphic.com